Abstract
Aflibercept therapy in diabetic macular oedema – own experience
- Department of Ophthalmology, District Hospital No 2 in Jastrzębie Zdrój, Poland
- Department of Ophthalmology, Medical University of Silesia, Katowice, Poland
- Department of Ophthalmology and Ocular Oncology, Jagiellonian Medical University, Kraków, Poland
Purpose
The aim of our study was to evaluate the outcomes of intravitreal aflibercept injections in patients with diabetic macular edema.
Material and methods
Twenty-five patients (15 men, 10 women) aged 45–65 (mean 57) with diabetes mellitus type 2 (28 eyes with diabetic macular edema) were analysed retrospectively. The mean duration of diabetes was 13.5 years. All patients were treated with insulin, oral antidiabetic drugs were additionally used in 8 cases. All patients (28 eyes) received 5 intravitreal injections of aflibercept (2.0 mg) at one month interval. The best corrected visual acuity and mean central retinal thickness (3D OCT 2000 Topcon) were evaluated at baseline and at the end of treatment. The follow up was 6 months.
Results
There was a significant improvement of best corrected visual acuity and central retinal thickness in the study group of 25 patients.
Conclusion
Intravitreal injections of aflibercept offer an improvement in visual acuity and central retinal anatomy in patients with diabetic macular edema.
Keywords
diabetic macular edema (DME), intravitreal injection of aflibercept, anti-vascular endothelial growth factor (anti-VEGF), central retinal thickness (CRT), optical coherence tomography (OCT)
Integrated with
